Mutant JAK3 FERMents ATLL

Blood

Volumn 118, Issue 14, 2011, Pages 3759-3760

  Pesu, Marko ^a  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ERYTHROCYTE BAND 4.1 PROTEIN; EZRIN; INTERLEUKIN 3; JANUS KINASE 3; MOESIN; RADIXIN; TOFACITINIB; UNCLASSIFIED DRUG;

CANCER PATIENT; CANCER SCREENING; HUMAN; MOLECULAR MODEL; MUTATION; NONHUMAN; NOTE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN STRUCTURE; SIGNAL TRANSDUCTION; T CELL LEUKEMIA; WILD TYPE;

EID: 80053654233     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-08-373282     Document Type: Note

References (10)

1. Russell SM, Tayebi N, Nakajima H, et al. Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development. Science. 1995;270(5237):797-800.
2. Walters DK, Mercher T, Gu TL, et al. Activating alleles of JAK3 in acute megakaryoblastic leukemia. Cancer Cell. 2006;10(1):65-75.
3. Mullighan CG, Zhang J, Harvey RC, et al. JAK mutations in high-risk childhood acute lymphoblastic leukemia. Proc Natl Acad Sci U S A. 2009;106(23):9414-9418.
4. Elliott NE, Cleveland SM, Grann V, Janik J, Waldmann TA, Davé UP. FERM domain mutations induce gain of function in JAK3 in adult T-cell leukemia/ lymphoma. Blood. 2011;118(14):3911-3921.
5. Yamaoka K, Saharinen P, Pesu M, Holt VE III, Silvennoinen O, O'Shea JJ. The Janus kinases (Jaks). Genome Biol. 2004;5(12):253.
6. Zhou YJ, Chen M, Cusack NA, et al. Unexpected effects of FERM domain mutations on catalytic activity of Jak3: structural implication for Janus kinases. Mol Cell. 2001;8(5):959-969. (Pubitemid 34031799)
7. Changelian PS, Flanagan ME, Ball DJ, et al. Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science. 2003;302(5646):875- 878. (Pubitemid 37339629)
8. Ju W, Zhang M, Jiang JK, et al. CP-690,550, a therapeutic agent, inhibits cytokine-mediated Jak3 activation and proliferation of T cells from patients with ATL and HAM/ TSP. Blood. 2011;117(6):1938-1946.
9. Coombs JH, Bloom BJ, Breedveld FC, et al. Improved pain, physical functioning and health status in patients with rheumatoid arthritis treated with CP-690,550, an orally active Janus kinase (JAK) inhibitor: results from a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2010;69(2):413-416.
10. Verstovsek S, Kantarjian H, Mesa RA, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med. 2010;363(12):1117-1127.